Cancer clinical trials in the region Occitanie
395 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Liver and bile duct cancer
#NCT06330064
#2023-509632-26-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required BCLC stage (Barcelona Clinic Liver Cancer)
B
C
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Breast cancer
#NCT06330064
#2023-509632-26-00
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Breast cancer
#NCT06330064
#2023-509632-26-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Skin cancer
#NCT06330064
#2023-509632-26-00
Cohorte 13 (Mélanome cutané)
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Prostate cancer
#NCT07332455
#2025-523874-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
2 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2
Lung cancer
Prostate cancer
Bladder / Urinary Tract / Urethral cancer
#NCT05875168
#2023-507937-14-00
Parties 1 et 2
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
5 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Multiple myeloma
#NCT06953960
#2024-517140-65-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
BCL2/6
t(11;14)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Abbvie
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 2 (Optimisation de la dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 1 (Escalade de dose et Backfilling)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT05751798
#2024-514826-22-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
OSE Immunotherapeutics